• NeOnc Technologies posted a net loss of about $62 million for fiscal 2025, with about 73% tied to non-cash stock-based compensation and one-time listing-related advisory fees.
• Net cash used in operating activities totaled $20.4 million, while normalized core operating cash burn was about $10.1 million after excluding $9.6 million of listing-related advisory payments and a $0.7 million litigation settlement.
• Chairman and CEO Amir Heshmatpour bought about $300,000 of NTHI stock over the past week as management pointed to near-term clinical catalysts.
• NEO212 expects a Type B End-of-Phase FDA meeting within the next four weeks, while NEO100 Phase 2a is fully enrolled with an interim data readout expected in about four months.
• NeOnc said it raised about $13 million in gross proceeds in a first-quarter 2026 private placement, using part of the funds to repay short-term convertible debt and satisfy accrued obligations.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neonc Technologies Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604140900PRIMZONEFULLFEED9689131) on April 14, 2026, and is solely responsible for the information contained therein.